EUCTR2009-011662-28-IT进行中（未招募）不适用
Exploratory study on inflammatory immune response related to endothelial dysfunction in HIV-infected na?ve patients treated with abacavir compared to tenofovir-based regimens. - ABRACADABRA
AZIENDA OSPEDALIERA SAN GERARDO DI MONZA0 个研究点开始时间: 2009年11月19日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed informed consent in accordance with GCP and local regulatory requirements prior to trial participation - HIV-1-infected males or females >18 years of age - Positive serology for HIV (ELISA) confirmed by Western Blot - CD4 + cell count between 250-350 cells/L - HIV-RNA < 100.000 cp/ml - BMI <30 - No previous antiretroviral treatment - Negative pregnancy test at least 14 days before the beginning of treatment, women of childbearing potential must be using a highly effective method of contraception to avoid pregnancy throughout the study - Study drugs susceptibility based on HIV-1 genotypic resistance test
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Presence of HLA-B 5701 - Current smoker - Presence of diabetes - Presence of active inflammatory requiring anti-inflammatory therapy - Presence of opportunistic infections - Actual or previous cardiovascular diseases - Prior history of bone diseases - Actual or previous autoimmune disease - Previous documented altered expression of endothelial molecules and activation markers on CD4+ lymphocytes - Adequate renal function defined as a calculated creatinine clearance (CLCr) > 50 ml/min according to the MDRD formula The estimate was calculated using the Modification of Diet in Renal Diseases (MDRD) formula: eGFR (MDRD) = 186 x serum creatinine -1.154 x age -0.203 x 0.742 (if female) x 1.21 (if black) - Framinghan score > 10% (age, sex, systolic blood pressure, total cholesterol, HDL cholesterol, smoking status) www.chip.dk/tools.aspx - Presence of family history of cardiovascular disease Presence of thyroid disfunctions - Known intolerance or allergies to the investigational drugs treatments - Use of immunomodulant substances, growth factors, cytokines (e.g. interferon, cyclosporine, hydrohyurea, interleukin 2) or vaccines within 3 months - Use of lipid-lowering therapy is allowed if stable ≥ 12 weeks before and throughout study - Have systemic treatment with corticosteroid (e.g. chronic treatment with prednisone) or hormone therapy or chronic treatment with high dose non steroidal anti-inflammatory drugs (e.g. ibuprofene) within 3 months prior to study enter or are expected to receive these during the study - Ongoing therapy with nephrotoxic drugs (e.g. aminoglycosides, amphotericine B, vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, tacrolimus) or in 3 months prior to baseline or are expected to receive these during the study - Patients who are receiving systemic treatment for malignant disease - Pregnant or breast-feeding patients - Any current known clinical or symptomatic laboratory parameter Grade 4. Asymptomatic laboratory parameter will be permitted at the discretion of the investigator if deemed clinically appropriate (excluding adverse events and laboratory parameters mentioned in the exclusion/inclusion criteria) - Karnofsky index < 50 - Use of medications during the course of the study which are known to alter serum lipid levels, including growth hormone, anabolic steroids, megestrol, thalidomide, pentoxyfylline, systemic ketoconzole, cyclosporine or prolonged pharmacologic doses of glucocorticoids or testosterone preparations. Subjects who require hormone replacement therapy for endocrine conditions (e.g., testosterone, estrogen, progesterone, hydrocortisone, thyroid hormone) are allowed to participate, as long as they are receiving a physiologic replacement dose.
研究者
相似试验
进行中（未招募）
1 期
A study investigating if markers for inflammation in the blood in patients with prostate cancer is affected by type of hormonal treatment received.Patients with advanced prostate cancer and pre-existing cardiovascular diseaseMedDRA version: 19.1Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 100000004864EUCTR2016-004120-39-SERegion Skåne
已完成
不适用
Prospective study on evaluation of immune response after SARS-CoV-2 vaccinatioHealthy SubjectJPRN-UMIN000045492Shionogi & Co., Ltd.143
进行中（未招募）
不适用
Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomideMultiple sclerosisMedDRA version: 14.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-001160-21-DEsanofi-aventis recherche & developpement120
进行中（未招募）
不适用
Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomideMultiple sclerosisEUCTR2011-001160-21-ATsanofi-aventis recherche & developpement120
已完成
Unknown
A study for evaluating the immune response by ingestion of fermented plant extractHealthy adultJPRN-UMIN000052021EP Mediate Co., Ltd.36